News & Events

News


Monday September 28, 2020

Neurocrine Biosciences to Present New Data Analyses of Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the American Neurological Association 2020 Virtual Meeting

- ONGENTYS, the First and Only Once-Daily COMT Inhibitor, Led to Greater Reductions in Overnight "Off" Time and Time to Morning "On" Time Compared to Entacapone When Used as an Add-On Therapy in Patients with Parkinson's Disease with Motor Fluctuations in a Post-Hoc, Sub-Group Analysis of the Phase


Monday September 14, 2020

Neurocrine Biosciences Announces Once-Daily ONGENTYS® (opicapone) Now Available in the U.S. as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes

- ONGENTYS, the First and Only FDA-Approved Once-Daily COMT Inhibitor, Decreases "Off" Time and Increases "On" Time Without Troublesome Dyskinesia When Added to Levodopa/Carbidopa   - FDA Approval of ONGENTYS Supported by Data from 38 Clinical Studies, Including Two Multinational Phase III Clinical


Friday September 11, 2020

Neurocrine Biosciences Presents New Data Analyses Demonstrating Efficacy of FDA-Approved Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the MDS Virtual Congress 2020

- Data Demonstrated that Newly Approved ONGENTYS Significantly Reduced "Off" Time as an Add-On Therapy in Patients with Parkinson's Disease Taking Levodopa/Carbidopa only in a Pooled Post-Hoc, Sub-Group Analysis of Phase III Studies   - ONGENTYS Significantly Increased "On" Time When Used as the


Friday September 11, 2020

Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson's Disease

-- Data for Investigational Gene Therapy Treatment NBIb-1817 (VY-AADC) Presented at the MDS Virtual Congress 2020 --   - NBIb-1817 Treatment Showed Sustained Improvement in Motor Function, Including Greater "On" Time without Troublesome Dyskinesia and Reduction in Unified Parkinson's Disease Rating


Tuesday September 08, 2020

Neurocrine Biosciences to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

Live Webcast will be on September 14, 2020 SAN DIEGO , Sept. 8, 2020 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Morgan Stanley 18 th Annual Global Healthcare Conference at 1:30 p.m. ET on Monday, September 14, 2020 .

Events